var data={"title":"Penicillin G (intravenous and short-acting intramuscular): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Penicillin G (intravenous and short-acting intramuscular): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6743?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=penicillin-g-intravenous-and-short-acting-intramuscular-drug-information\" class=\"drug drug_general\">see &quot;Penicillin G (intravenous and short-acting intramuscular): Drug information&quot;</a> and <a href=\"topic.htm?path=penicillin-g-intravenous-and-short-acting-intramuscular-patient-drug-information\" class=\"drug drug_patient\">see &quot;Penicillin G (intravenous and short-acting intramuscular): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207660\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Pfizerpen;</li>\n      <li>Pfizerpen-G</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207661\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Crystapen</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049245\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Penicillin</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11444110\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>General dosing, susceptible infection (non-CNS)</b> (<i>Red Book</i> [AAP 2015]): IM, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Body weight &lt;1 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">PNA &le;14 days: 25,000 to 50,000 units/kg/<b>dose</b> every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">PNA 15 to 28 days: 25,000 to 50,000 units/kg/<b>dose</b> every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Body weight &ge;1 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">PNA &le;7 days: 25,000 to 50,000 units/kg/<b>dose</b> every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">PNA 8 to 28 days: 25,000 to 50,000 units/kg/<b>dose</b> every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anthrax, systemic</b> (AAP [Bradley 2014])<b>:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Non-CNS infection:</i> <b>Note:</b> Use in combination with clindamycin, linezolid, doxycycline, or rifampin for &ge;2 to 3 weeks until clinical stability is achieved (ie, appear well with no signs or symptoms of active infection and can tolerate oral therapy); treatment must be followed by prophylaxis for a total antibiotic course of 60 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GA 32 to 34 weeks:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">PNA &le;7 days: IV: 200,000 units/kg/day in divided doses every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">PNA 8 to 28 days: IV: 300,000 units/kg/day in divided doses every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GA &gt;34 to 37 weeks:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">PNA &le;7 days: IV: 300,000 units/kg/day in divided doses every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">PNA 8 to 28 days: IV: 400,000 units/kg/day in divided doses every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GA &gt;37 weeks:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">PNA &le;7 days: IV: 300,000 units/kg/day in divided doses every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">PNA 8 to 28 days: IV: 400,000 units/kg/day in divided doses every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Meningitis:</i> <b>Note:</b> Use in combination with a fluoroquinolone plus linezolid, clindamycin, rifampin, or chloramphenicol for &ge;2 to 3 weeks until clinical stability is achieved (ie, appear well with no signs or symptoms of active infection and can tolerate oral therapy); treatment must be followed by prophylaxis for a total antibiotic course of 60 days</p>\n    <p style=\"text-indent:-4em;margin-left:8em;\">GA 32 to 34 weeks:</p>\n    <p style=\"text-indent:-4em;margin-left:10em;\">PNA &le;7 days: IV: 200,000 units/kg/day in divided doses every 12 hours</p>\n    <p style=\"text-indent:-4em;margin-left:10em;\">PNA 8 to 28 days: IV: 300,000 units/kg/day in divided doses every 8 hours</p>\n    <p style=\"text-indent:-4em;margin-left:8em;\">GA &gt;34 to 37 weeks:</p>\n    <p style=\"text-indent:-4em;margin-left:10em;\">PNA &le;7 days: IV: 300,000 units/kg/day in divided doses every 8 hours</p>\n    <p style=\"text-indent:-4em;margin-left:10em;\">PNA 8 to 28 days: IV: 400,000 units/kg/day in divided doses every 6 hours</p>\n    <p style=\"text-indent:-4em;margin-left:8em;\">GA &gt;37 weeks:</p>\n    <p style=\"text-indent:-4em;margin-left:10em;\">PNA &le;7 days: IV: 300,000 units/kg/day in divided doses every 8 hours</p>\n    <p style=\"text-indent:-4em;margin-left:10em;\">PNA 8 to 28 days: IV: 400,000 units/kg/day in divided doses every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Meningitis:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Group B streptococcus (<i>Red Book</i> [AAP 2015]):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">PNA 0 to 7 days: 250,000 to 450,000 units/kg/day in divided doses every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">PNA 8 to 28 days: 450,000 to 500,000 units/kg/day in divided doses every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Other susceptible organisms (IDSA [Tunkel 2004]):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">PNA 0 to 7 days: 150,000 units/kg/day in divided doses every 8 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">PNA 8 to 28 days: 200,000 units/kg/day in divided doses every 6 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Syphilis, congenital</b> (CDC [Workowski 2015]): IV: <b>Note:</b> If &gt;1 day of therapy is missed, the entire course needs to be restarted.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">PNA 0 to 7 days: 50,000 units/kg/<b>dose</b> every 12 hours; at PNA 8 days increase to 50,000 units/kg/<b>dose</b> every 8 hours for a total of 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">PNA &ge;8 days: 50,000 units/kg/ <b>dose</b> every 8 hours for a total of 10 days</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049238\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=penicillin-g-intravenous-and-short-acting-intramuscular-drug-information\" class=\"drug drug_general\">see &quot;Penicillin G (intravenous and short-acting intramuscular): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infection</b> (<i>Red Book</i> [AAP 2015]): Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild to moderate infection: IM, IV: 100,000 to 150,000 units/kg/day in divided doses every 6 hours; maximum daily dose: 8 million units/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe infections: IM, IV: 200,000 to 300,000 units/kg/day in divided doses every 4 to 6 hours; maximum daily dose: 24 million units/<b>day</b>; <b>Note:</b> Use highest dose in range for CNS infections.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Anthrax, systemic; treatment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Non-CNS infection; preferred agent for penicillin-susceptible strains: Infants, Children, and Adolescents: IV: 400,000 units/kg/day in divided doses every 4 hours; maximum dose: 4 million units/dose; use in combination with clindamycin, linezolid, doxycycline, or rifampin for &ge;14 days until clinical stability is achieved (ie, appear well with no signs or symptoms of active infection and can tolerate oral therapy); treatment must be followed by prophylaxis for a total antibiotic course of 60 days (AAP [Bradley 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Meningitis; preferred agent for penicillin-susceptible strains: Infants, Children, and Adolescents: IV: 400,000 units/kg/day in divided doses every 4 hours; maximum dose: 4 million units/dose; use in combination with a fluoroquinolone plus linezolid, clindamycin, rifampin, or chloramphenicol for &ge;2 to 3 weeks until clinical stability is achieved (ie, appear well with no signs or symptoms of active infection and can tolerate oral therapy); treatment must be followed by prophylaxis for a total antibiotic course of 60 days (AAP [Bradley 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Clostridial myonecrosis (gas gangrene):</b> Infants, Children, and Adolescents: IV: 250,000 to 400,000 units/kg/day in divided doses every 4 to 6 hours with or without clindamycin (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Diphtheria:</b> Infants, Children, and Adolescents: IM, IV: 150,000 to 250,000 units/kg/day in divided doses every 6 hours for 7 to 10 days. AAP suggests a duration of 14 days (<i>Red Book</i> [AAP 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Endocarditis, bacterial; treatment</b>: Children and Adolescents: IV: 200,000 to 300,000 units/kg/day in divided doses every 4 hours; maximum daily dose: 24 million units/<b>day</b>; treat for at least 4 weeks; longer durations may be necessary; may use in combination with gentamicin for some resistant organisms (AHA [Baltimore 2015]). <b>Note:</b> For endocarditis from rat-bite fever/haverhill fever, the manufacturer recommends a lower dose of 150,000 to 250,000 units/kg/day in divided doses every 4 hours; maximum daily dose: 20 million units/<b>day</b>.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Lyme disease:</b> Infants, Children, and Adolescents: IV: 200,000 to 400,000 units/kg/day in divided doses every 4 hours; maximum daily dose: 24 million units/<b>day</b> (AAN [Halperin 2007]; IDSA [Wormser 2006])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Meningitis:</b> <b>Note:</b> Dosing varies based on organism being treated.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Group B <i>streptococcus</i>: Infants: IV: 450,000 to 500,000 units/kg/day divided every 6 hours (<i>Red Book </i>[AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>S. pneumoniae:</i> Infants, Children, and Adolescents: IV: 250,000 to 400,000 units/kg/day divided every 4 to 6 hours (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Other susceptible organisms: Infants, Children, and Adolescents: IV: 300,000 units/kg/day divided every 4 to 6 hours; maximum daily dose: 24 million units/<b>day</b> (IDSA [Tunkel 2004])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Meningococcal disease:</b> Infants, Children, and Adolescents: IV: 300,000 units/kg/day in divided doses every 4 to 6 hours; maximum daily dose: 12 million units/<b>day</b> (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pneumonia, community-acquired (CAP):</b> Infants &gt;3 months and Children:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Empiric treatment or <i>S. pneumoniae</i> (moderate to severe; MICs to penicillin &le;2.0 mcg/mL): IV: 200,000 to 250,000 units/kg/day divided every 4 to 6 hours (IDSA/PIDS [Bradley 2011])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Alternate dosing (AAP recommendation): IV: 250,000 to 400,000 units/kg/day divided every 4 to 6 hours (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Group A <i>Streptococcus</i> (moderate to severe): IV: 100,000 to 250,000 units/kg/day divided every 4 to 6 hours (IDSA/PIDS [Bradley 2011])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Skin and soft tissue necrotizing infections due to <i>Clostridium</i> species:</b> Infants, Children, and Adolescents: IV: 60,000 to 100,000 units/kg/<b>dose</b> every 6 hours; use in combination with clindamycin and continue until further debridement is not necessary, patient has clinically improved, and patient is afebrile for 48 to 72 hours (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Streptococcal skin infections, including skin and soft tissue necrotizing infections:</b> Infants, Children, and Adolescents: IV: 60,000 to 100,000 units/kg/<b>dose</b> every 6 hours; maximum dose: 4 million units/dose; use in combination with clindamycin for necrotizing infections and continue until further debridement is not necessary, patient has clinically improved, and patient is afebrile for 48 to 72 hours (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Syphilis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Congenital: Infants and Children: IV: 50,000 units/kg/<b>dose</b> every 4 to 6 hours for 10 days (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Neurosyphilis (including ocular syphilis):</p>\n    <p style=\"text-indent:-4em;margin-left:10em;\">Infants and Children: IV: 50,000 units/kg/<b>dose</b> every 4 to 6 hours for 10 to 14 days; maximum daily dose: 24 million units/<b>day</b></p>\n    <p style=\"text-indent:-4em;margin-left:10em;\">Adolescents: IV: 3 to 4 million units every 4 hours or as a continuous infusion for 10 to 14 days; maximum daily dose: 24 million units/<b>day</b> (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Tetanus; treatment: </b>Infants, Children, and Adolescents: IV: 100,000 units/kg/day in divided doses every 4 to 6 hours for 7 to 10 days; maximum daily dose: 12 million units/<b>day</b> (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Usual dosage range: </b>IM, IV: 12 to 24 million units/day in divided doses every 4 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Clostridium </i></b>\n      <b>species:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: IV: 20 million units/day in divided doses every 4 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Skin and soft tissue necrotizing infections: IV: 2 to 4 million units every 4 to 6 hours; use in combination with clindamycin and continue until further debridement is not necessary, patient has clinically improved, and patient is afebrile for 48 to 72 hours (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Diphtheria (adjunctive therapy to antitoxin and for prevention of carrier state)</b>: IV: 2 to 3 million units/day in divided doses every 4 to 6 hours for 10 to 12 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Endocarditis, treatment</b> (AHA [Baddour 2015): IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Enterococcus:</i> IV: 18 to 30 million units/day as continuous infusion or in divided doses every 4 hours; use in combination with other antibiotics based on susceptibility. Duration of therapy is dependent on valve type, patient response, and duration of symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Viridans group streptococcus (VGS) and S. bovis:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Native valve:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Highly penicillin-susceptible (MIC &le;0.12 mcg/mL): IV: 12 to 18 million units/day as continuous infusion or in divided doses every 4 or 6 hours for 4 weeks <b>or</b> 12 to 18 million units/day as continuous infusion or in divided doses every 6 hours for 2 weeks with concomitant gentamicin</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Relatively penicillin-resistant (MIC &gt;0.12 to &lt;0.5 mcg/mL): IV: 24 million units/day as continuous infusion or in divided doses every 4 or 6 hours for 4 weeks with concomitant gentamicin for the first 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Prosthetic valve: All strains: IV: 24 million units/day as continuous infusion or in divided doses every 4 or 6 hours for 6 weeks; concomitant treatment with gentamicin is determined based on susceptibility</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Group B<i> Streptococcus</i>;<i></i>maternal dose for neonatal prophylaxis:</b> IV: 5 million units once then 2.5 to 3 million units every 4 hours until delivery (CDC 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Neurosyphilis (including ocular syphilis):</b> IV: 18 to 24 million units/day in divided doses every 4 hours (or by continuous infusion) for 10 to 14 days (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer's labeling: Infants, Children, Adolescents, and Adults: IM, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Uremic patients with CrCl &gt;10 mL/minute/1.73 m<sup>2</sup>: Administer a normal dose followed by 50% of the normal dose every 4 to 5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;10 mL/minute/1.73 m<sup>2</sup>: Administer a normal dose followed by 50% of the normal dose every 8 to 10 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemodialysis: Dialyzable</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Alternate recommendation: Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &gt;50 mL/minute: No dosage adjustments are necessary (Aronoff 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR 10 to 50 mL/minute: Administer 75% of the normal dose (Aronoff 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &lt;10 mL/minute: Administer 20% to 50% of the normal dose (Aronoff 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days) (Heintz 2009): Administer a normal dose followed by either 25% to 50% of normal dose every 4 to 6 hours <b>or</b> 50% to 100% of normal dose every 8 to 12 hours. <i>For mild to moderate infections,</i> administer 0.5 to 1 million units every 4 to 6 hours <b>or</b> 1 to 2 million units every 8 to 12 hours. <i>For neurosyphilis, endocarditis, or serious infections,</i> administer up to 2 million units every 4 to 6 hours; administer after dialysis on dialysis days <b>or</b> supplement with 500,000 units after dialysis. <b>Note:</b> Dosing dependent on the assumption of 3 times weekly, complete IHD sessions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1 to 2 L/hour and minimal residual renal function) and should not supersede clinical judgment:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CVVH: Loading dose of 4 million units, followed by 2 million units every 4 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CVVHD: Loading dose of 4 million units, followed by 2 to 3 million units every 4 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CVVHDF: Loading dose of 4 million units, followed by 2 to 4 million units every 4 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> All patients: There are no dosage adjustments provided in the manufacturer's labeling; however, the manufacturer's labeling recommends further adjustment of doses adjusted for renal impairment in patients with both renal and hepatic impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207638\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as potassium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 20,000 units/mL (50 mL); 40,000 units/mL (50 mL); 60,000 units/mL (50 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection, as potassium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pfizerpen-G: 5,000,000 units (1 ea); 20,000,000 units (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pfizerpen-G: 5,000,000 units (1 ea); 20,000,000 units (1 ea) [pyrogen free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5,000,000 units (1 ea); 20,000,000 units (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection, as potassium [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pfizerpen: 5,000,000 units (1 ea); 20,000,000 units (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 20,000,000 units (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection, as sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5,000,000 units (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207622\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049248\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM: Administer IM by deep injection in the upper outer quadrant of the buttock. Administer injection around-the-clock to promote less variation in peak and trough levels. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Usually administered by intermittent infusion. In some centers, large doses may be administered by continuous IV infusion. The potassium or sodium content of the dose should be considered when determining the infusion rate. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent IV: Infuse over 15 to 30 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous IV infusion: Daily dose may be administered as a continuous infusion over 24 hours, or smaller increments (eg, 24 hour dose divided into two 12-hour infusions)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207654\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Penicillin G potassium powder for injection should be stored below 86&deg;F (30&deg;C). Following reconstitution, solution may be stored for up to 7 days under refrigeration. Premixed bags for infusion should be stored at -20&deg;C or -4&deg;F; frozen bags may be thawed at 25&deg;C (77&deg;F) or in a refrigerator (5&deg;C [41&deg;F]). Once thawed, solution is stable for 14 days at 5&deg;C (41&deg;F) or for 24 hours at 25&deg;C (77&deg;F). Do not refreeze once thawed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Penicillin G sodium powder for injection should be stored at 20&deg;C to 25&deg;C (68&deg;F to 87&deg;F). Once reconstituted, the manufacturer recommends refrigeration (2&deg;C to 8&deg;C [36&deg;F to 46&deg;F]) and use within 3 days of reconstitution. After further dilution to 2,500 to 50,000 units/mL in either D5W or NS (in PVC bags or elastomeric pump containers), one study demonstrated stability when stored under refrigeration for up to 21 days (Hossain 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049247\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of infections (including sepsis, empyema, pneumonia, pericarditis, endocarditis, meningitis, anthrax, botulism, gas gangrene, and tetanus) caused by susceptible organisms; active against some gram-positive organisms, generally not <i>Staphylococcus aureus</i>; some gram-negative organisms such as <i>Neisseria gonorrhoeae</i> and some anaerobes and spirochetes (FDA approved in all ages)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207689\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Penicillin may be confused with penicillamine</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207686\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Localized phlebitis, local thrombophlebitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Coma (high doses), hyperreflexia (high doses), myoclonus (high doses), seizure (high doses)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Contact dermatitis, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Electrolyte disturbance (high doses)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Pseudomembranous colitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Neutropenia, positive direct Coombs test (rare, high doses)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Anaphylaxis, hypersensitivity reaction (immediate and delayed), serum sickness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Immunologic: Jarisch-Herxheimer reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Local: Injection site reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Renal: Acute interstitial nephritis (high doses), renal tubular disease (high doses)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207645\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to any penicillin or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for beta-lactams (eg, penicillins and cephalosporins) is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207626\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactic/hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactic) reactions have been reported in patients on penicillin therapy, especially with a history of beta-lactam hypersensitivity (including cephalosporins) or history of sensitivity to multiple allergens. Use with caution in asthmatic patients. If a serious reaction occurs, discontinue treatment and institute supportive measures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neurovascular damage: Avoid intra-arterial administration or injection into or near major peripheral nerves or blood vessels since such injections may cause severe and/or permanent neurovascular damage.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment recommended. In the presence of concomitant hepatic impairment, further dosage adjustment may be needed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorders: Use with caution in patients with a history of seizure disorder; high levels, particularly in the presence of renal impairment, may increase risk of seizures.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Concurrent drug therapy issues:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neonates: Neonates may have decreased renal clearance of penicillin and require frequent dosage adjustments depending on age.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Electrolyte imbalance: Product contains sodium and potassium; high doses of IV therapy may alter serum levels. If high doses (eg, &gt;10 million units) are used, administer at a slower rate (eg, &gt;30 minutes for intermittent IV infusion).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299838\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of OAT3</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207631\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12687&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acemetacin: May increase the serum concentration of Penicillins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: Penicillins may increase the serum concentration of Methotrexate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Penicillins. Management: Avoid the routine use of penicillins and probenecid, but this combination may be used advantageously in select cases with careful monitoring. Monitor for toxic effects of penicillins if probenecid is initiated or the dose is increased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teriflunomide: May increase the serum concentration of OAT3 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracyclines: May diminish the therapeutic effect of Penicillins.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Penicillins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5720623\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Penicillin G crosses the placenta. Maternal use of penicillins has generally not resulted in an increased risk of adverse fetal effects. Penicillin G is the drug of choice for treatment of syphilis during pregnancy and penicillin G (parenteral/aqueous) is the drug of choice for the prevention of early-onset Group B Streptococcal (GBS) disease in newborns (consult current guidelines) (CDC (RR-10) 2010; CDC [Workowski 2015]). When IV therapy is required for anthrax infection in pregnant and postpartum women, penicillin G may be used as an alternative agent (Meaney-Delman 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049244\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Periodic serum electrolytes, renal and hematologic function tests, cardiac and hematologic function tests during prolonged/high-dose therapy; observe for signs and symptoms of anaphylaxis during first dose and changes in bowel frequency</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207625\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Interferes with bacterial cell wall synthesis during active multiplication, causing cell wall death and resultant bactericidal activity against susceptible bacteria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207644\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Poor penetration across blood-brain barrier, despite inflamed meninges</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Relative diffusion from blood into CSF: Poor unless meninges inflamed (exceeds usual MICs)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CSF:blood level ratio: Inflamed meninges: 2% to 6%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates: &lt;6 days of age: 3.1 hours; &ge;14 days of age: 1.4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Normal renal function: 31 to 50 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">End-stage renal disease (ESRD): 6 to 20 hours (Aronoff 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: IV: Immediately after infusion</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (58% to 85% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049252\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Penicillin G potassium: 1.7 mEq of potassium and 0.3 mEq of sodium per 1 million units of penicillin G </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Penicillin G sodium: 2 mEq of sodium per 1 million units of penicillin G</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323647\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Penicillin G Potassium Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5000000 unit (1): $42.18</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20000000 unit (1): $138.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Penicillin G Sodium Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5000000 unit (1): $57.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Pfizerpen Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5000000 unit (1): $15.19</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20000000 unit (1): $60.76</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Pfizerpen-G Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5000000 unit (1): $15.19</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20000000 unit (1): $60.76</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207648\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Benpen (AU, NZ);</li>\n      <li>Bentapen (PH);</li>\n      <li>Broncobiot (PE);</li>\n      <li>Lascacilin (PY);</li>\n      <li>Pencarv (PH);</li>\n      <li>Pengesod (MX);</li>\n      <li>Penicilina Northia (AR);</li>\n      <li>Penicillin G (BG);</li>\n      <li>Penicillin G- Natrium (AT);</li>\n      <li>Pisacilina (CO);</li>\n      <li>Sodipen (MX);</li>\n      <li>Unicil 1 Mega (CO)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed, Philadelphia, PA: American College of Physicians, 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association [published correction appears in <i>Circulation</i>. 2015;132(17):e215]. <i>Circulation</i>. 2015;132(15):1435-1486.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baltimore RS, Gewitz M, Baddour LM, et al. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;132(15):1487-515.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-pediatric-drug-information/abstract-text/26373317/pubmed\" target=\"_blank\" id=\"26373317\">26373317</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Byington CL, Shah SS, et al, &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;, <i>Clin Infect Dis</i>, 2011, 53(7):e25-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-pediatric-drug-information/abstract-text/21880587/pubmed\" target=\"_blank\" id=\"21880587\">21880587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Peacock G, Krug SE, et al. Pediatric anthrax clinical management. <i>Pediatrics</i>. 2014;133(5):e1411-1436.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-pediatric-drug-information/abstract-text/24777226/pubmed\" target=\"_blank\" id=\"24777226\">24777226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control, &quot;Prevention of Perinatal Group B Streptococcal Disease,&quot; <i>MMWR</i>, 2010, 59(RR10)1-32.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Greene HJ, Burkhart B, Hobby GL. Excretion of penicillin in human milk following parturition. <i>Am J Obstet Gyn.</i> 1946;51:732-733.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-pediatric-drug-information/abstract-text/21025164/pubmed\" target=\"_blank\" id=\"21025164\">21025164</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Halperin JJ, Shapiro ED, Logigian E, et al, &quot;Practice Parameter: Treatment of Nervous System Lyme Disease (an Evidence-Based Review),&quot; <i>Neurology</i>, 2007, 69(1):91-102.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-pediatric-drug-information/abstract-text/17522387/pubmed\" target=\"_blank\" id=\"17522387\">17522387</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heintz BH, Matzke GR, and Dager WE, &quot;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&quot; <i>Pharmacotherapy</i>, 2009, 29(5):562-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-pediatric-drug-information/abstract-text/19397464/pubmed\" target=\"_blank\" id=\"19397464\">19397464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hossain MA, Friciu M, Aubin S, Leclair G. Stability of penicillin G sodium diluted with 0.9% sodium chloride injection or 5% dextrose injection and stored in polyvinyl chloride bag containers and elastomeric pump containers. <i>Am J Health Syst Pharm</i>. 2014;71(8):669-673.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-pediatric-drug-information/abstract-text/24688042/pubmed\" target=\"_blank\" id=\"24688042\">24688042</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Matsuda S. Transfer of antibiotics into maternal milk. <i>Biol Res Pregnancy Perinatol.</i> 1984;5(2):57-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-pediatric-drug-information/abstract-text/6743732/pubmed\" target=\"_blank\" id=\"6743732\">6743732</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meaney-Delman D, Zotti ME, Creanga AA, et al. Special considerations for prophylaxis for and treatment of anthrax in pregnant and postpartum women. <i>Emerg Infect Dis</i>. 2014;20(2).<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-pediatric-drug-information/abstract-text/24457117/pubmed\" target=\"_blank\" id=\"24457117\">24457117</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Osmon DR, Berbari EF, Berendt AR, et al, &quot;Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guidelines by the Infectious Diseases Society of America,&quot; <i>Clin Infect Dis</i>, 2013, 56(1):e1-e25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-pediatric-drug-information/abstract-text/23223583/pubmed\" target=\"_blank\" id=\"23223583\">23223583</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Penicillin G potassium for injection (penicillin G [parenteral/aqueous]) [prescribing information]. Deerfield IL: Baxter Healthcare Corporation; August 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Penicillin G sodium for injection (penicillin G [parenteral/aqueous]) [prescribing information]. Princeton, NJ: Sandoz Inc; October 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prober CG, Stevenson DK, Benitz WE. The use of antibiotics in neonates weighing less than 1200 grams. <i>Pediatr Infect Dis J</i>. 1990;9(2):111-121.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-pediatric-drug-information/abstract-text/2179837 /pubmed\" target=\"_blank\" id=\"2179837 \">2179837 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robinson DC, Cookson TL, Grisafe JA. Concentration guidelines for parenteral antibiotics in fluid-restricted patients. <i>Drug Intell Clin Pharm</i>. 1987;21(12):985-989.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-pediatric-drug-information/abstract-text/3428165 /pubmed\" target=\"_blank\" id=\"3428165 \">3428165 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2014;59(2):e10-52. Erratum in Stevens DL, et al. <i>Clin Infect Dis</i>. 2014; 59:147-159.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-pediatric-drug-information/abstract-text/24973422/pubmed\" target=\"_blank\" id=\"24973422\">24973422</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trotman RL, Williamson JC, Shoemaker DM, et al, &quot;Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,&quot; <i>Clin Infect Dis</i>, 2005, 41(8):1159-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-pediatric-drug-information/abstract-text/16163635/pubmed\" target=\"_blank\" id=\"16163635\">16163635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tunkel AR, Hartman BJ, Kaplan SL, et al, &quot;Practice Guidelines For the Management of Bacterial Meningitis,&quot; <i>Clin Infect Dis</i>, 2004, 39(9):1267-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-pediatric-drug-information/abstract-text/15494903/pubmed\" target=\"_blank\" id=\"15494903\">15494903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Workowski KA, Bolan GA, Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2015. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137. Erratum in <i>MMWR Recomm Rep</i>. 2015;64(33):924.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-pediatric-drug-information/abstract-text/26042815/pubmed\" target=\"_blank\" id=\"26042815\">26042815</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wormser GP, Dattwyler RJ, Shapiro ED, et al, &quot;The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America,&quot; <i>Clin Infect Dis</i>, 2006, 43(9):1089-134.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-pediatric-drug-information/abstract-text/17029130/pubmed\" target=\"_blank\" id=\"17029130\">17029130</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12687 Version 121.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F207660\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F207661\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1049245\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11444110\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1049238\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F207638\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F207622\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1049248\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F207654\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1049247\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F207689\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F207686\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F207645\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F207626\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299838\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F207631\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5720623\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1049244\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F207625\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F207644\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1049252\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323647\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F207648\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12687|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=penicillin-g-intravenous-and-short-acting-intramuscular-drug-information\" class=\"drug drug_general\">Penicillin G (intravenous and short-acting intramuscular): Drug information</a></li><li><a href=\"topic.htm?path=penicillin-g-intravenous-and-short-acting-intramuscular-patient-drug-information\" class=\"drug drug_patient\">Penicillin G (intravenous and short-acting intramuscular): Patient drug information</a></li></ul></div></div>","javascript":null}